72 Jane Street 
New York N Y 10014 ^ 
(212)675-7173 A 
Coalition for 
Responsible Genetic Research 
ADVISORY COUNCIL 
John S Bird M D 
Dr Irwin Brois 
Helen Caldicott M 0 * 
Dr Liebe Cavelieri* 
|ohn C Cobb M 0 ' 
Dr Douglas DeNike 
Dr Key Dumukei* 
W lack Frumm M 0 
Solomon Carb MO' 
Steven Havas M D * 
Or Ruth Hubbard* 
Dr Marvin Kalkstein* 
J.R. Kent M D 
Dr Jonathan King* 
Or Sheldon Krimsky* 
Elliot Linaer* 
Pamela Lippe’ 
loyce Milton 
Lewis Mumtord* 
Dr Stuart Newman* 
Christine Oliver M D * 
David Ozonoff M 0 * 
Dr Barbara Rosenberg* 
David Straton M D * 
Dr Ceorge Wald*. 
Nobel Laureate 
Susanna Waterman* 
O Joseph Weizenbaum * 
Dr Susan Wnght* 
*E aecutive Committee 
MEMBERSHIP 
PARTIAL LISTINC 
Walter Askmas MO 
David R Brower 
Rev Roger Burgess 
Sir MacFarlane Burnet. 
Nobel Laureate 
Stuart Chase 
Citizens Rights Committee 
Clen C Cobb M D 
Dr C David Elm. 
William D Furst M D 
Reverend David A Furuness 
Mariano L Calaineva M D 
W B Gamble Jr M D 
F M Colomb M D 
Dr Mario A Conzalez 
Harold I Hams M D 
Or Kenneth L Jackson 
Father Walter T Kelleher 
Hadley Kirkman M D 
Dr Laura Kratz 
Henry D Lauson M D 
Dr Herbert Manning 
Edwm F Matthews Jr 
Edward Miller M D 
Robert Murphy M D 
Maurice L Origenes M D 
Dr Aurelio Peccei 
Henry Pinkerton M D 
Eliot Porter 
Dr Jerome Prager 
Dr Steven Price 
Sister Mary E Reichert 
Abbv Rockefeller 
Lewis M Schiffer M D 
Solomon Carb MO 
Mem ben hip Secretary 
Francine R Simring 
Executive Director 
•S 
9 
I 
COMMENTS ON PROPOSED REVISED GUIDELINES FOR 
RECOMBINANT DNA RESEARCH 
FEDERAL REGISTER, JULY 28, 1978 
PART IV 
INTROVUCTION 
This section of comments on the proposed revised Guide- 
lines concerning protection of the health of the potentially 
exposed worker is the third of a three-part report submitted 
by the Coalition for Responsible Genetic Research. 
Part I - Structures and Procedures 
Part II - Technical Analysis and Comments 
Part III- Protection of Employees 
The following comments indicate areas of inadequacy, re- 
commend improvements and changes, and also touch on the mechanism 
for policy change: 
I . InduAtAsUil Regulation 
The Guidelines provide only for voluntary compliance by 
industry with its standards and procedures, "...provision is 
now made for the private sector to register voluntarily its re- 
combinant DNA activities with the NIH." (p. 33045) Because of 
the voluntary nature of the directive, industry will not be sub- 
ject to sanctions for non-compliance. This is especially of con- 
cern because volume-oriented production sharply increases the 
probabilities of biologic mishap and worker exposure. 
[A-329] 
